Catherine Boucher, FNP | |
570 Long Point Rd Ste 200, Mount Pleasant, SC 29464-7940 | |
(843) 881-0320 | |
(843) 881-5453 |
Full Name | Catherine Boucher |
---|---|
Gender | Female |
Speciality | Nurse Practitioner - Family |
Location | 570 Long Point Rd Ste 200, Mount Pleasant, South Carolina |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1457727679 | NPI | - | NPPES |
SC77017818 | Other | SC | MEDICARE PTAN |
NP3370 | Medicaid | SC |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207N00000X | Dermatology | 19695 (South Carolina) | Secondary |
363LF0000X | Nurse Practitioner - Family | 19695 (South Carolina) | Primary |
Entity Name | Mt Pleasant Dermatology |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1821048828 PECOS PAC ID: 6204721285 Enrollment ID: O20040218000682 |
News Archive
New research from a team of researchers in Taiwan indicates that a peptide fragment derived from cow's milk, known as lactoferricin B25 (LFcinB25), exhibited potent anticancer capability against human stomach cancer cell cultures.
GlaxoSmithKline has announced that the U.S. Food and Drug Administration (FDA) has issued a not approvable letter for the supplemental drug application for the 500/50 strength of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) in the treatment of patients with chronic obstructive pulmonary disease (COPD).
Japan's favorite beverage might be offering more than just a relaxing tea break.
Comorbid substance use increases diagnostic uncertainty in patients admitted to hospital with psychosis, Australian research shows.
› Verified 7 days ago
Mailing Address | Practice Location Address |
---|---|
Catherine Boucher, FNP 32782 Cedar Dr Ste 2, Millville, DE 19967-6919 Ph: (302) 448-6874 | Catherine Boucher, FNP 570 Long Point Rd Ste 200, Mount Pleasant, SC 29464-7940 Ph: (843) 881-0320 |
News Archive
New research from a team of researchers in Taiwan indicates that a peptide fragment derived from cow's milk, known as lactoferricin B25 (LFcinB25), exhibited potent anticancer capability against human stomach cancer cell cultures.
GlaxoSmithKline has announced that the U.S. Food and Drug Administration (FDA) has issued a not approvable letter for the supplemental drug application for the 500/50 strength of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) in the treatment of patients with chronic obstructive pulmonary disease (COPD).
Japan's favorite beverage might be offering more than just a relaxing tea break.
Comorbid substance use increases diagnostic uncertainty in patients admitted to hospital with psychosis, Australian research shows.
› Verified 7 days ago